Its unclear how much employers will pay for GLP-1s through the direct-to-employer compared to a traditional medical plan
The 3 mg strength is often used at the beginning and is not considered the full glucose-lowering maintenance dose
The global obesity drug market is projected to reach USD 100 billion in 2030, with the GLP-1 injection market alone expected to increase five-fold from 2024 to 2030, reaching USD 81 billion
Out of all the study participants, 39.6 percent were prescribed semaglutide for type 2 diabetes, 42.6 percent were prescribed liraglutide for type 2 diabetes, 11.1 percent were prescribed semaglutide for obesity, and 6.7 percent were prescribed liraglutide for obesity
In other secondary outcomes, physical quality of life (QOL) improved by 3.75 points on the 36-item Short Form Survey, version 2, in the semaglutide group